Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
INTERVENTIONAL
Inicio: 17 de nov de 2021
ID: NCT04988295
Completado
Fase 2
ClinicalTrials.gov
An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired
INTERVENTIONAL
Inicio: 21 de jun de 2011
ID: NCT01342952
Terminado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension
INTERVENTIONAL
Inicio: 23 de ene de 2019
ID: NCT03689244
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS
INTERVENTIONAL
Inicio: 5 de abr de 2018
ID: NCT03329092
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Assessment of the Efficacy in Reduction of Nasal Polyp Size in Patients With Nasal Polyposis and Concomitant Asthma.
INTERVENTIONAL
Inicio: 26 de mar de 2019
ID: NCT03681093
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
INTERVENTIONAL
Inicio: 18 de jun de 2019
ID: NCT03955146
Activo, no recluta
Fase 3
ClinicalTrials.gov
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
INTERVENTIONAL
Inicio: 3 de may de 2022
ID: NCT05298423
Completado
Fase 3
ClinicalTrials.gov
A Phase 2 Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active-Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
INTERVENTIONAL
Inicio: 1 de oct de 2004
ID: NCT00097357
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)
INTERVENTIONAL
Inicio: 27 de mar de 2017
ID: NCT02798471
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, 12-Week (With an Extension to 52 Weeks in a Subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared to BGF Delivered by MDI HFA in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
INTERVENTIONAL
Inicio: 27 de sept de 2022
ID: NCT05573464
Completado
ClinicalTrials.gov
PREPARE STUDY: PRevalence of the Eosinophilic Phenotype Among SeveRE Asthma Patients in AstraZeneca International Region. A Multinational, Cross-Sectional, Multicenter Study
OBSERVATIONAL
Inicio: 15 de may de 2019
ID: NCT03931954
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
INTERVENTIONAL
Inicio: 5 de sept de 2023
ID: NCT06033833
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)
INTERVENTIONAL
Inicio: 26 de ago de 2019
ID: NCT04053634
Activo, no recluta
Fase 3
ClinicalTrials.gov
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
INTERVENTIONAL
Inicio: 22 de mar de 2019
ID: NCT03815643
Completado
Fase 3
ClinicalTrials.gov
Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension
INTERVENTIONAL
Inicio: 7 de jul de 2010
ID: NCT01112306
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)
INTERVENTIONAL
Inicio: 11 de ene de 2011
ID: NCT01244191
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women With Chronic Cough and Stress Urinary Incontinence
INTERVENTIONAL
Inicio: 10 de may de 2020
ID: NCT04193176
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
INTERVENTIONAL
Inicio: 1 de ago de 2011
ID: NCT01437735
Reclutando
Fase 3
ClinicalTrials.gov
A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON)
INTERVENTIONAL
Inicio: 24 de ago de 2023
ID: NCT06023589
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19
INTERVENTIONAL
Inicio: 12 de ene de 2021
ID: NCT04732949
Anterior
1
...
29
30
31
...
434
Siguiente
Filtros